[go: up one dir, main page]

US20150073024A1 - 1,2,4-Oxadiazole Derivatives as Immunomodulators - Google Patents

1,2,4-Oxadiazole Derivatives as Immunomodulators Download PDF

Info

Publication number
US20150073024A1
US20150073024A1 US14/478,759 US201414478759A US2015073024A1 US 20150073024 A1 US20150073024 A1 US 20150073024A1 US 201414478759 A US201414478759 A US 201414478759A US 2015073024 A1 US2015073024 A1 US 2015073024A1
Authority
US
United States
Prior art keywords
cancer
compound
amino acid
formula
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/478,759
Inventor
Pottayil Govindan Nair Sasikumar
Muralidhara Ramachandra
Seetharamaiah Setty Sudarshan Naremaddepalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Publication of US20150073024A1 publication Critical patent/US20150073024A1/en
Assigned to AURIGENE DISCOVERY TECHNOLOGIES LIMITED reassignment AURIGENE DISCOVERY TECHNOLOGIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SASIKUMAR, POTTAYIL GOVINDAN NAIR, NAREMADDEPALLI, SEETHARAMAIAH SETTY SUDARSHAN, RAMACHANDRA, MURALIDHARA
Priority to US15/298,539 priority Critical patent/US9771338B2/en
Priority to US15/713,671 priority patent/US10173989B2/en
Priority to US16/192,030 priority patent/US10590093B2/en
Priority to US16/806,872 priority patent/US10961205B2/en
Priority to US17/192,279 priority patent/US11512060B2/en
Priority to US17/981,695 priority patent/US12037321B2/en
Assigned to AURIGENE ONCOLOGY LIMITED reassignment AURIGENE ONCOLOGY LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Priority to US18/747,813 priority patent/US20240400525A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds and their derivatives therapeutically useful as immune modulators.
  • the invention also relates to pharmaceutical compositions comprising the said 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds and their derivatives as therapeutic agents.
  • PD-1 Programmed cell death-1
  • PD-L1 or PD-L2 are members of the CD28 superfamily that delivers negative signals upon interaction with its two ligands, PD-L1 or PD-L2.
  • PD-1 and its ligands are broadly expressed and exert a wider range of immunoregulatory roles in T cells activation and tolerance compared with other CD28 members.
  • PD-1 and its ligands are involved in attenuating infectious immunity and tumor immunity, and facilitating chronic infection and tumor progression.
  • the biological significance of PD-1 and its ligand suggests the therapeutic potential of manipulation of PD-1 pathway against various human diseases (Ariel Pedoeem et al., Curr Top Microbiol Immunol. (2011); 350:17-37).
  • T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response (Li Shi, et al., Journal of Hematology & Oncology 2013, 6:74).
  • PD-1 programmed cell death protein-1
  • Several PD-1 pathway inhibitors have shown robust activity in various phases of on-going clinical trials (R D Harvey, Clinical Pharmacology & Therapeutics (2014); 96 2, 214-223).
  • PD-1 Programmed death-1
  • PD-L1 or PD-L2 The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiological regulation of the immune system.
  • a major functional role of the PD-1 signaling pathway is the inhibition of self-reactive T cells, which serve to protect against autoimmune diseases. Elimination of the PD-1 pathway can therefore result in the breakdown of immune tolerance that can ultimately lead to the development of pathogenic autoimmunity.
  • tumor cells can at times co-opt the PD-1 pathway to escape from immunosurveillance mechanisms. Therefore, blockade of the PD-1 pathway has become an attractive target in cancer therapy.
  • the present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • PD1 programmed cell death 1
  • 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds or a pharmaceutically acceptable salt or a stereoisomer thereof provided which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • PD1 programmed cell death 1
  • the present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I):
  • Q is S or O
  • R 1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
  • R 2 is hydrogen or —CO-Aaa
  • Aaa is an amino acid residue Thr or Ser; wherein a C-terminus thereof is a free terminus, is amidated or is esterified;
  • R 3 is a side chain of amino acid Asn, Asp, Gln or Glu;
  • R 4 and R 5 independently are hydrogen or absent
  • R 6 is hydrogen, alkyl or acyl
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer and processes for preparing thereof.
  • PD1 programmed cell death 1
  • methods for suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway in a subject by administering 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof or pharmaceutical compositions thereof.
  • FIGS. 1A-1B depict the chemical synthetic scheme for Compound 1.
  • FIG. 2 depicts the chemical synthetic scheme for Compound 2.
  • FIG. 3 depicts the chemical synthetic scheme for Compound 7.
  • the present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents useful in methods for treating disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
  • the present invention relates to compounds of formula (I)
  • Q is S or O
  • R 1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
  • R 2 is hydrogen or —CO-Aaa
  • Aaa is an amino acid residue Thr or Ser; a C-terminus thereof is a free terminus, is amidated or is esterified;
  • R 3 is side chain of amino acid Asn, Asp, Gln, or Glu
  • R 4 and R 5 independently are hydrogen or absent
  • R 6 is hydrogen, alkyl or acyl
  • the present invention provides compounds of formula (IA)
  • R 1 , R 3 and Aaa are as defined in formula (I).
  • the present invention provides compounds of formula (IB)
  • R 1 and R 3 are the same as defined in formula (I).
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 1 is a side chain of Ser or Thr;
  • R 2 is —CO-Aaa;
  • Aaa is an amino acid residue Thr or Ser; wherein C-terminus is free; and
  • R 3 is a side chain of Asn or Glu.
  • R 1 is a side chain of Ser, optionally substituted with C 1-5 alkyl such as methyl.
  • R 6 is acyl such as butyryl.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound as disclosed, and a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutical composition further comprising at least one of an anticancer agent, chemotherapy agent, or antiproliferative compound.
  • the compounds as disclosed in the present invention are formulated for pharmaceutical administration.
  • the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament.
  • the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament for the treatment of cancer or infectious disease.
  • the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament for the treatment of bacterial, viral and fungal infections.
  • the present invention provides a method of treatment of cancer, wherein the method comprises administration of an effective amount of the compound of the present invention or of a pharmaceutical composition thereof to the subject in need thereof.
  • the present invention provides a method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof such that the immune response in the subject is modulated.
  • the present invention provides a method of inhibiting growth of tumour cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • PD1 programmed cell death 1
  • tumour cells include cancer such as, but not limited to, bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hogkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cnacer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or reter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS
  • the present invention provides a method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signalling pathway such that the subject is treated for the infectious disease.
  • PD1 programmed cell death 1
  • Still yet another embodiment of the present invention provides a method of treating bacterial, viral and fungal infections in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the bacterial, viral and fungal infections.
  • PD1 programmed cell death 1
  • the infectious disease includes but not limited to HIV, Influenza, Herpes, Giardia , Malaria, Leishmania , the pathogenic infection by the virus Hepatitis (A, B, & C), herpes virus (e.g., VZV, HSV-I, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus, pathogenic infection by the bacteria chlamydia , rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, men
  • coli legionella , diphtheria, salmonella , bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria, pathogenic infection by the fungi Candida ( albicans, krusei, glabrata, tropicalis , etc.), Cryptococcus neoformans, Aspergillus ( fumigatus, niger , etc.), Genus Mucorales ( mucor, absidia, rhizophus ), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum , and pathogenic infection by the parasites Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp
  • the compounds of the present invention may be used as single drugs or as a pharmaceutical composition in which the compound is mixed with various pharmacologically acceptable materials.
  • compositions are usually administered by oral or inhalation routes, but can be administered by parenteral administration route.
  • compositions can be administered, for example, by orally, intravenous infusion, topically, intraperitoneally, intravesically or intrathecally.
  • parenteral administration includes but not limited to intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • Oral administration, parenteral administration, subcutaneous administration and intravenous administration are the preferred methods of administration.
  • the dosage of the compounds of the present invention varies depending on age, weight, symptom, therapeutic efficacy, dosing regimen and/or treatment time. Generally, they may be administered by oral or inhalation routes, in an amount of 1 mg to 100 mg per time, from once a couple of days, once 3 days, once 2 days, once a day to a couple of times a day, in the case of an adult, or continuously administered by oral or inhalation routes from 1 to 24 hours a day. Since the dosage is affected by various conditions, an amount less than the above dosage may sometimes work well enough, or higher dosage may be required in some cases.
  • the compounds of the present invention may be administered in combination with other drugs for (1) complementation and/or enhancement of prevention and/or therapeutic efficacy of the preventive and/or therapeutic drug of the present invention, (2) dynamics, absorption improvement, dosage reduction of the preventive and/or therapeutic drug of the present invention, and/or (3) reduction of the side effects of the preventive and/or therapeutic drug of the present invention.
  • a concomitant medicine comprising the compounds of the present invention and other drug may be administered as a combination preparation in which both components are contained in a single formulation, or administered as separate formulations.
  • the administration by separate formulations includes simultaneous administration and administration with some time intervals.
  • the compound of the present invention can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present invention.
  • the administration method of the respective drugs may be the same or different.
  • the dosage of the other drug can be properly selected, based on a dosage that has been clinically used.
  • the compounding ratio of the compound of the present invention and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof.
  • the other drug may be used in an amount of 0.01 to 100 parts by mass, based on 1 part by mass of the compound of the present invention.
  • the other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion.
  • the other drug that complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention includes not only those that have already been discovered, but those that will be discovered in future, based on the above mechanism.
  • the concomitant medicine can be used for any diseases, as long as it complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention.
  • the compound of the present invention can be used with an existing chemotherapeutic concomitantly or in a mixture form.
  • the chemotherapeutic include an alkylation agent, nitrosourea agent, antimetabolite, anticancer antibiotics, vegetable-origin alkaloid, topoisomerase inhibitor, hormone drug, hormone antagonist, aromatase inhibitor, P-glycoprotein inhibitor, platinum complex derivative, other immunotherapeutic drugs and other anticancer drugs.
  • a cancer treatment adjunct such as a leucopenia (neutropenia) treatment drug, thrombocytopenia treatment drug, antiemetic and cancer pain intervention drug, concomitantly or in a mixture form.
  • the compound(s) of the present invention can be used with other immunomodulators and/or a potentiating agent concomitantly or in a mixture form.
  • the immunomodulator include various cytokines, vaccines and adjuvants.
  • these cytokines, vaccines and adjuvants that stimulates immune responses include but not limited to GM-CSF, M-CSF, G-CSF, interferon- ⁇ , ⁇ , or ⁇ , IL-1, IL-2, IL-3, IL-12, Poly (I:C) and C p G.
  • the potentiating agents includes cyclophosphamide and analogs of cyclophosphamide, anti-TGF ⁇ and Imatinib (Gleevac), a mitosis inhibitor, such as paclitaxel, Sunitinib (Sutent) or other antiangiogenic agents, an aromatase inhibitor, such as letrozole, an A2a adenosine receptor (A2AR) antagonist, an angiogenesis inhibitor, anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.
  • a mitosis inhibitor such as paclitaxel, Sunitinib (Sutent) or other antiangiogenic agents
  • an aromatase inhibitor such as letrozole
  • A2a adenosine receptor (A2AR) antagonist an angiogenesis inhibitor
  • anthracyclines oxaliplatin
  • doxorubicin TLR4 antagonists
  • the term “optionally substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: alkyl, alkoxy, acyl, halo, and hydroxyl. It is understood that the substituent may be further substituted.
  • alkyl refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, having from one to twenty carbon atoms (i.e., C 1-20 alkyl) or one to ten carbon atoms (i.e., C 1-10 alkyl) or one to five carbon atoms (i.e., C 1-5 alkyl) and which is attached to the rest of the molecule by a single bond, e.g., including but not limited to methyl, ethyl, propyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • acyl refers to RC(O)—, wherein R is alkyl as defined above.
  • examples of acyl group include, but are not limited to —C(O)CH 3 , —C(O)CH 2 CH 3 , —C(O)(CH 2 ) 2 CH 3 , —C(O)(CH 2 ) 3 CH 3 , —C(O)(CH 2 ) 4 CH 3 , —C(O)(CH 2 ) 5 CH 3 —C(O)(CH 2 ) 6 CH 3 and —C(O)(CH 2 ) 8 CH 3 .
  • aminoated C-terminus refers to that the C-terminal of the amino acid in amide form.
  • amide form refers to primary, secondary and/or tertiary amides and may be represented by the formula —C(O)NR x R y , wherein each of R x and R y independently represents hydrogen or alkyl.
  • amino refers to —NH 2 group. Unless set forth or recited to the contrary, all amino groups described or claimed herein may be substituted or unsubstituted.
  • amino acid refers to amino acids having L or D stereochemistry at the alpha carbon.
  • Optional substituent on amino acid means replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent, in case of amino acid containing hydroxyl group such as Serine or Threonine, the hydroxyl group can be substituted with the specified substituent.
  • aryl refers to C 4 -C 10 carbocyclic aromatic system containing one or two rings wherein such rings may be fused.
  • aryl groups include, but are not limited to phenyl and naphthyl.
  • arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group (e.g., benzyl and the like).
  • carboxylic acid refers to —COOH group.
  • Coupled agent means a compound that reacts with the hydroxyl moiety of a carboxy moiety thereby rendering it susceptible to nucleophilic attack.
  • Coupling agents of this type are known in the art and include, but are not limited to, EDCI, HATU, HOBt, DIC and DCC.
  • esters refers to (C 1 -C 6 ) linear or branched alkyl, (C 4 -C 10 )aryl, (C 4 -C 10 )heteroaryl or arylalkyl esters.
  • esterified C-terminus refers to that the C-terminal of the amino acid in ester form.
  • free C-terminus refers to that the C-terminal of the amino acid in —CO 2 H form.
  • halogen or halo includes fluorine, chlorine, bromine or iodine.
  • “Hydroxy” or “Hydroxyl” refers to —OH group.
  • “Pharmaceutically acceptable salt” is taken to mean an active ingredient, which comprises a compound of the formula (I) in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
  • the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • stereoisomer/stereoisomers refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of formula (I), wherever they are chiral or when they bear one or more double bond.
  • the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
  • diastereomers are formed from the mixture by reaction with an optically active resolving agent.
  • optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids.
  • optically active resolving agent for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel.
  • subject includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • domestic animals e.g., household pets including cats and dogs
  • non-domestic animals such as wildlife.
  • therapeutically effective amount refers to sufficient amount of the compound(s) of the present invention that (i) treats or prevents the particular disease, disorder or syndrome (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, disorder or syndrome or (iii) prevents or delays the onset of one or more symptoms of the particular disease, disorder or syndrome described herein.
  • the therapeutically effective amount of the drug may decrease the number of cancer cells; decrease the cancer size; inhibit (i.e., slow to some extent and alternatively stop) cancer cell infiltration into peripheral organs; suppress (i.e., slow to some extent and alternatively stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer.
  • the therapeutic effective amount is an amount sufficient to decrease or alleviate an infectious diseases, the symptoms of an infections caused by bacterial, viral and fungal.
  • An embodiment of the present invention provides the preparation of compounds of formula (I) according to the procedures of the following examples, using appropriate materials. Those skilled in the art will understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. Moreover, by utilizing the procedures described in detail, one of ordinary skill in the art can prepare additional compounds of the present invention.
  • the starting materials are generally available from commercial sources such as Sigma-Aldrich, USA or Germany; Chem-Impex USA; G.L. Biochem, China and Spectrochem, India.
  • Analytical HPLC method Analytical HPLC was performed using on ZIC HILIC 200 A° column (4.6 mm ⁇ 250 mm, 5 ⁇ m), Flow rate: 1.0 mL/min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate, Buffer B: Acetonitrile, Equilibration of the column with 90% buffer B and elution by a gradient of 90% to 40% buffer B during 30 min.
  • Preparative HPLC Method Preparative HPLC was performed using on SeQuant ZIC HILIC 200 A° column (10 mm ⁇ 250 mm, 5 ⁇ m), Flow rate: 5.0 mL/min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate (adjust to pH-4 with Acetic Acid), Buffer B: Acetonitrile, Equilibration of the column with 90% buffer B and elution by a gradient of 90% to 40% buffer B during 20 min.
  • LCMS was performed on AP1 2000 LC/MS/MS triple quad (Applied bio systems) with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Agilent LC/MSD VL single quad with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Shimadzu LCMS 2020 single quad with Prominence UFLC system with SPD-20 A DAD.
  • FIG. 1A illustrates Steps 1a, 1b and 1c.
  • Step 1a Ethylchloroformate (1.5 g, 13.78 mmol) and N-Methylmorpholine (1.4 g, 13.78 mmol) were added to a solution of compound 1a (3 g, 11.48 mmol) in THF (30 mL) and stirred at ⁇ 20° C. After 20 min. liquid ammonia (0.77 g, 45.92 mmol) was added to the active mixed anhydride formed in-situ and stirred at 0-5° C. for 20 min. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate.
  • Step 1 b Trifluroacetic anhydride (9.7 g, 46.0 mmol) was added to a solution of compound 1b (8 g, 30.7 mmol) in pyridine (24.3 g, 307.0 mmol) and stirred at room temperature for 3 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with NaHCO 3 , citric acid, brine solution, dried over Na 2 SO 4 and evaporated under reduced pressure to afford 7 g of compound 1c (Yield: 94.0%). LCMS: 187.2 (M-′Bu)+.
  • Step 1c Hydroxylamine hydrochloride (3 g, 43.37 mmol) and potassium carbonate (6 g, 43.37 mmol) were added to a solution of compound 1c (7 g, 28.01 mmol) in EtOH (70 mL) and stirred at 90° C. for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with brine solution, dried over Na 2 SO 4 and evaporated under reduced pressure.
  • Step 1d Deoxo-Fluor® (1.83 g, 8.3 mmol) was added to a solution of Fmoc-Asn(Trt)-OH (4.5 g, 7.5 mmol) in CH 2 Cl 2 (50 mL) and stirred at 0° C. for 3 h. Then CH 2 Cl 2 was evaporated and triturated with hexane, decanted and evaporated under vacuum to get the corresponding acid fluoride. NMM (1.17 g, 11.6 mmol) and compound 1d (1.6 g, 5.8 mmol) in THF were added to the acid fluoride and stirred at room temperature for 12 h.
  • Step 1e To compound 1e (2.3 g, 2.7 mmol) in CH 2 Cl 2 (10 mL) diethylamine (10 mL) was added and the reaction mixture was stirred at room temperature for 30 min. The resulting solution was concentrated in vacuum to get gummy residue. The crude compound was purified by neutral alumina column chromatography (Eluent: 0-50% ethyl acetate in hexane then 0-5% methanol in chloroform) to get 1.4 g of 1f (Yield: 90%). LCMS: 636.5 (M+Na) + .
  • Step 1f To a solution of compound 1f (0.45 g) in CH 2 Cl 2 (5 mL), trifluoroacetic acid (5 mL) and catalytic amount of triisopropylsilane were added and stirred for 3 h at room temperature to remove the acid sensitive protecting groups. The resulting solution was concentrated in vacuum to afford 0.29 g of crude compound 1 which was purified using prep-HPLC method described under experimental conditions.
  • FIG. 2 illustrates Steps 2a and 2b.
  • Step 2a The urea linkage was carried out by the coupling compound 1f (2.7 g, 4.39 mmol) in THF (30 mL) at room temperature with compound 2b (1.67 g, 4.39 mmol). The coupling was initiated by the addition of TEA (0.9 g, 8.78 mmol) in THF (10 m L) and the resultant mixture was stirred at room temperature. After completion of 20 h, THF was evaporated from the reaction mass, and partitioned between water and ethyl acetate.
  • reaction mixture was diluted with CH 2 Cl 2 and washed with water and 5.0 M citric acid solution, dried over Na 2 SO 4 and evaporated under reduced pressure to get crude compound 2b, which was further purified by silica gel column chromatography (Eluent: 0-20% ethyl acetate in hexane) to yield 2.1 g (58.9%) of 2b.
  • the compound was synthesised using similar procedure as depicted in Example 2 for synthesising compound 2 using H-Thr( t Bu)-O t Bu instead of H-Ser( t Bu)-O t Bu (in synthesis of compound 2b) to yield 0.35 g crude material of the title compound.
  • FIG. 3 illustrates Steps 7a, 7b and 7c.
  • Step 7a The compound 7a was synthesised using similar procedure as for compound 2a (Example 2, step 2a) using H-Thr( t Bu)-OMe instead of H-Ser( t Bu)-OtBu to get crude material which was further purified by silica gel column chromatography (Eluent: 0-50% ethyl acetate in hexane) to get 2.0 g of compound 7a (Yield: 74%). LCMS: 829.2 (M+H) + .
  • Step 7b To a solution of compound 7a (0.35 g, 4.0 mmol) in THF (5 mL) was added lithium hydroxide (0.026 g, 0.63 mmol) at 0° C. and the mixture was stirred for 2 h at room temperature. The completion of the reaction was confirmed by TLC analysis. THF was evaporated from the reaction mass, and partitioned between water and ethyl acetate. Organic layer was washed with citric acid, brine solution, dried over Na 2 SO 4 and evaporated under reduced pressure to afford 7b, which was further purified by silica gel column chromatography (Eluent: 0-5% methanol in DCM) to get 0.3 g of product 7b (Yield: 86.7%). LCMS 815.2 (M+H) + .
  • Step 7c Compound 7b (0.295 g, 0.39 mmol) was anchored to Rink amide resin (0.7 g, 0.55 mmol/g) using HOBT (0.072 g, 0.54 mmol) and DIC (0.068 g, 0.54 mmol) method in DMF (10 mL). The resin was stirred for 12 h at room temperature. The resin was washed with DCM, DMF and DCM and dried. The target compound was cleaved from the rink amide resin using TFA (5 mL) and catalytic amount of TIPS. The resin was allowed to remain at room temperature for 2 h with occasional stirring.
  • Example 2 The compound was synthesised using similar procedure as depicted in Example 2 (compound 2) using Fmoc-Glu(O t Bu)-OH instead of Fmoc-Asn(Trt)-OH to get 0.4 g crude material of the title compound.
  • mice PD-L1 Recombinant mouse PD-L1 (rm-PDL-1, cat no: 1019-B7-100 & rh-PDL-1, cat no: 156-B7-100, R&D Systems) were used as the source of PD-L1.
  • Working concentrations were titrated from 10 ⁇ M to 1 ⁇ M. (eBioscience-650850-85); 0.05% Trypsin and 0.02% EDTA (SIGMA 59417C); 96-well format ELISA plates (Corning CLS3390); BD FACS caliber (E6016); Recombinant mouse B7-H1/PDL1 Fc Chimera, (rm-PD-L1 cat no: 1019-B7-100).
  • Splenocytes harvested in a 50 mL falcon tube by mashing mouse spleen in a 40 ⁇ m cell strainer were further treated with 1 mL ACK lysis buffer for 5 min at room temperature. After washing with 9 mL of RPMI complete media, cells were re-suspended in 3 mL of 1 ⁇ PBS in a 15 mL tube. 3 mL of Histopaque was added carefully to the bottom of the tube without disturbing overlaying splenocyte suspension. After centrifuging at 800 ⁇ g for 20 min at room temperature, the opaque layer of splenocytes was collected carefully without disturbing/mixing the layers. Splenocytes were washed twice with cold 1 ⁇ PBS followed by total cell counting using Trypan Blue exclusion method and used further for cell based assays.
  • Splenocytes were cultured in RPMI complete media (RPMI+10% fetal bovine serum+1 mM sodium pyruvate+10,000 units/mL penicillin and 10,000 ⁇ g/mL streptomycin) and maintained in a CO 2 incubator with 5% CO 2 at 37° C.
  • RPMI complete media RPMI+10% fetal bovine serum+1 mM sodium pyruvate+10,000 units/mL penicillin and 10,000 ⁇ g/mL streptomycin
  • CFSE is a dye that passively diffuses into cells and binds to intracellular proteins. 1 ⁇ 10 6 cells/mL of harvested splenocytes were treated with 5 ⁇ M of CFSE in pre-warmed 1 ⁇ PBS/0.1% BSA solution for 10 min at 37° C. Excess CFSE was quenched using 5 volumes of ice-cold culture media to the cells and incubated on ice for 5 min. CFSE labelled splenocytes were further given three washes with ice cold complete RPMI media.
  • CFSE labelled 1 ⁇ 10 5 splenocytes added to wells containing either MDA-MB231 cells (1 ⁇ 10 5 cells cultured in high glucose DMEM medium) or recombinant human PDL-1 (100 ng/mL) and test compounds.
  • Splenocytes were stimulated with anti-mouse CD3 and anti-mouse CD28 antibody (1 ⁇ g/mL each), and the culture was further incubated for 72 h at 37° C. with 5% CO 2 .
  • Cells were harvested and washed thrice with ice cold FACS buffer and % proliferation was analyzed by flow cytometry with 488 nm excitation and 521 nm emission filters.
  • Percent splenocyte proliferation was analyzed using cell quest FACS program and percent rescue of splenocyte proliferation by compound was estimated after deduction of % background proliferation value and normalising to % stimulated splenocyte proliferation (positive control) as 100%.
  • Stimulated splenocytes Splenocytes+anti-CD3/CD28 stimulation
  • Background proliferation Splenocytes+anti-CD3/CD28+PD-L1
  • Compound proliferation Splenocytes+anti-CD3/CD28+PD-L1+Compound Compound effect is examined by adding required conc. of compound to anti-CD3/CD28 stimulated splenocytes in presence of ligand (PDL-1) (Table 4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This nonprovisional application claims the benefit of priority under 35 U.S.C. §119(a) of Indian provisional application number 4011/CHE/2013, filed on Sep. 6, 2013, which is hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Technical Field of the Invention
  • The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds and their derivatives therapeutically useful as immune modulators. The invention also relates to pharmaceutical compositions comprising the said 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds and their derivatives as therapeutic agents.
  • 2. Description of the Related Art
  • Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals upon interaction with its two ligands, PD-L1 or PD-L2. PD-1 and its ligands are broadly expressed and exert a wider range of immunoregulatory roles in T cells activation and tolerance compared with other CD28 members. PD-1 and its ligands are involved in attenuating infectious immunity and tumor immunity, and facilitating chronic infection and tumor progression. The biological significance of PD-1 and its ligand suggests the therapeutic potential of manipulation of PD-1 pathway against various human diseases (Ariel Pedoeem et al., Curr Top Microbiol Immunol. (2011); 350:17-37).
  • T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response (Li Shi, et al., Journal of Hematology & Oncology 2013, 6:74).
  • Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell down regulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in various phases of on-going clinical trials (R D Harvey, Clinical Pharmacology & Therapeutics (2014); 96 2, 214-223).
  • Programmed death-1 (PD-1) is a co-receptor that is expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiological regulation of the immune system. A major functional role of the PD-1 signaling pathway is the inhibition of self-reactive T cells, which serve to protect against autoimmune diseases. Elimination of the PD-1 pathway can therefore result in the breakdown of immune tolerance that can ultimately lead to the development of pathogenic autoimmunity. Conversely, tumor cells can at times co-opt the PD-1 pathway to escape from immunosurveillance mechanisms. Therefore, blockade of the PD-1 pathway has become an attractive target in cancer therapy. Current approaches include six agents that are either PD-1 and PD-L1 targeted neutralizing antibodies or fusion proteins. More than forty clinical trials are underway to better define the role of PD-1 blockade in variety of tumor types (Hyun-Tak Jin et al., Clinical Immunology (Amsterdam, Netherlands) (2014), 153(1), 145-152).
  • International applications WO 01/14557, WO 02/079499, WO 2002/086083, WO 03/042402, WO 2004/004771, WO 2004/056875, WO2006121168, WO2008156712, WO2010077634, WO2011066389, WO2014055897, WO2014059173, WO2014100079 and US patent U.S. Ser. No. 08/735,553 report PD-1 or PD-L1 inhibitory antibodies or fusion proteins.
  • Further, International applications, WO2011161699, WO2012/168944, WO2013144704 and WO2013132317 report peptides or peptidomimetic compounds which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • Still there is a need for more potent, better and/or selective immune modulators of PD-1 pathway. The present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.
    • SUMMARY OF THE INVENTION
  • In accordance with the present invention, 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds or a pharmaceutically acceptable salt or a stereoisomer thereof, provided which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • In one aspect, the present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I):
  • Figure US20150073024A1-20150312-C00001
  • wherein,
  • Q is S or O;
  • R1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
  • R2 is hydrogen or —CO-Aaa;
  • Aaa is an amino acid residue Thr or Ser; wherein a C-terminus thereof is a free terminus, is amidated or is esterified;
  • R3 is a side chain of amino acid Asn, Asp, Gln or Glu;
  • ----- is an optional bond;
  • R4 and R5 independently are hydrogen or absent;
  • R6 is hydrogen, alkyl or acyl;
  • or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer and processes for preparing thereof.
  • In yet another aspect of the present invention, there is provided methods for suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway in a subject by administering 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof or pharmaceutical compositions thereof.
  • In yet another aspect of the present invention, there is provided methods for inhibiting growth of tumour cells and/or metastasis in a subject by administering 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof or pharmaceutical compositions thereof.
  • In yet another aspect of the present invention, there is provided methods for treating an infectious disease or a bacterial, viral and fungal infections in a subject by administering 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof or pharmaceutical compositions thereof.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions and certain embodiments of the invention briefly summarized above are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
  • FIGS. 1A-1B depict the chemical synthetic scheme for Compound 1.
  • FIG. 2 depicts the chemical synthetic scheme for Compound 2.
  • FIG. 3 depicts the chemical synthetic scheme for Compound 7.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents useful in methods for treating disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
  • Each embodiment is provided by way of explanation of the invention, and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modification and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be used on another embodiment to yield a still further embodiment. Thus it is intended that the present invention cover such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features, and aspects of the present invention are disclosed in, or are obvious from, the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not to be construed as limiting the broader aspects of the present invention.
  • In one embodiment, the present invention relates to compounds of formula (I)
  • Figure US20150073024A1-20150312-C00002
  • wherein,
  • Q is S or O;
  • R1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
  • R2 is hydrogen or —CO-Aaa;
  • Aaa is an amino acid residue Thr or Ser; a C-terminus thereof is a free terminus, is amidated or is esterified;
  • R3 is side chain of amino acid Asn, Asp, Gln, or Glu;
  • ----- is an optional bond;
  • R4 and R5 independently are hydrogen or absent;
  • R6 is hydrogen, alkyl or acyl;
  • or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • In another embodiment, the present invention provides compounds of formula (IA)
  • Figure US20150073024A1-20150312-C00003
  • or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
  • R1, R3 and Aaa are as defined in formula (I).
  • In yet another further embodiment, the present invention provides compounds of formula (IB)
  • Figure US20150073024A1-20150312-C00004
  • or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
  • R1 and R3 are the same as defined in formula (I).
  • In yet another further embodiment, for the compound according to formula (I) Q is S.
  • In yet another further embodiment, for the compound according to formula (I) R4 is hydrogen.
  • In yet another further embodiment, for the compound according to formula (I) R5 is hydrogen.
  • The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
  • According to one embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which R1 is a side chain of Ser.
  • According to another embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which R1 is a side chain of Thr.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R2 is hydrogen.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R2 is —CO-Aaa.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which Aaa is Thr.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which Aaa is Ser.
  • According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which R3 is a side chain of Asn.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which R3 is a side chain of Asp.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which R3 is a side chain of Gln.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which R3 is side a chain of Glu.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R1 is a side chain of Ser or Thr; R2 is —CO-Aaa; Aaa is an amino acid residue Thr or Ser; wherein C-terminus is free; and R3 is a side chain of Asn or Glu.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which Q is O.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R1 is a side chain of Ser, optionally substituted with C1-5 alkyl such as methyl.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R6 is hydrogen.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R6 is acyl such as butyryl.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which R4 and R5 are absent.
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which C-terminus of Aaa is free (e.g. —CO2H form).
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which C-terminus of Aaa is esterified (e.g. —CO2Me form).
  • According to yet another embodiment, specifically provided are compounds of the formula (I) in which C-terminus of Aaa is amidated (e.g. —CONH2 form).
  • According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which one, more or all amino acid/s is/are D amino acid/s.
  • In an embodiment, specific compounds of formula (I) without any limitation are enumerated in Table 1 or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • TABLE 1
    Compound
    No. Structure
    1
    Figure US20150073024A1-20150312-C00005
    2
    Figure US20150073024A1-20150312-C00006
    3
    Figure US20150073024A1-20150312-C00007
    4
    Figure US20150073024A1-20150312-C00008
    5
    Figure US20150073024A1-20150312-C00009
    6
    Figure US20150073024A1-20150312-C00010
    7
    Figure US20150073024A1-20150312-C00011
    8
    Figure US20150073024A1-20150312-C00012
    9
    Figure US20150073024A1-20150312-C00013
    10
    Figure US20150073024A1-20150312-C00014
    11
    Figure US20150073024A1-20150312-C00015
    12
    Figure US20150073024A1-20150312-C00016
    13
    Figure US20150073024A1-20150312-C00017
    14
    Figure US20150073024A1-20150312-C00018
    15
    Figure US20150073024A1-20150312-C00019
    16
    Figure US20150073024A1-20150312-C00020
    17
    Figure US20150073024A1-20150312-C00021
    18
    Figure US20150073024A1-20150312-C00022
    19
    Figure US20150073024A1-20150312-C00023
    20
    Figure US20150073024A1-20150312-C00024
    21
    Figure US20150073024A1-20150312-C00025
    22
    Figure US20150073024A1-20150312-C00026
    23
    Figure US20150073024A1-20150312-C00027
    24
    Figure US20150073024A1-20150312-C00028
    25
    Figure US20150073024A1-20150312-C00029
  • In one embodiment, the present invention provides a pharmaceutical composition comprising the compound as disclosed, and a pharmaceutically acceptable carrier or diluent.
  • In another embodiment, the pharmaceutical composition further comprising at least one of an anticancer agent, chemotherapy agent, or antiproliferative compound.
  • The compounds as disclosed in the present invention are formulated for pharmaceutical administration.
  • In one embodiment, the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament.
  • In another embodiment, the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament for the treatment of cancer or infectious disease.
  • In one embodiment, the present invention provides use of the compounds as disclosed in the present invention for the preparation of a medicament for the treatment of bacterial, viral and fungal infections.
  • In one embodiment, the present invention provides a method of treatment of cancer, wherein the method comprises administration of an effective amount of the compound of the present invention or of a pharmaceutical composition thereof to the subject in need thereof.
  • In another embodiment the present invention provides a method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof such that the immune response in the subject is modulated.
  • In yet another embodiment the present invention provides a method of inhibiting growth of tumour cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signaling pathway.
  • The said tumour cells include cancer such as, but not limited to, bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hogkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cnacer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or reter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.
  • In yet another further embodiment the present invention provides a method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signalling pathway such that the subject is treated for the infectious disease.
  • Still yet another embodiment of the present invention provides a method of treating bacterial, viral and fungal infections in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention or a pharmaceutical composition thereof capable of inhibiting the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the bacterial, viral and fungal infections.
  • The infectious disease includes but not limited to HIV, Influenza, Herpes, Giardia, Malaria, Leishmania, the pathogenic infection by the virus Hepatitis (A, B, & C), herpes virus (e.g., VZV, HSV-I, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus, pathogenic infection by the bacteria chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, E. coli, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria, pathogenic infection by the fungi Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum, and pathogenic infection by the parasites Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, Nippostrongylus brasiliensis.
  • The compounds of the present invention may be used as single drugs or as a pharmaceutical composition in which the compound is mixed with various pharmacologically acceptable materials.
  • The pharmaceutical composition is usually administered by oral or inhalation routes, but can be administered by parenteral administration route. In the practice of this invention, compositions can be administered, for example, by orally, intravenous infusion, topically, intraperitoneally, intravesically or intrathecally. Examples of the parenteral administration includes but not limited to intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Oral administration, parenteral administration, subcutaneous administration and intravenous administration are the preferred methods of administration.
  • The dosage of the compounds of the present invention varies depending on age, weight, symptom, therapeutic efficacy, dosing regimen and/or treatment time. Generally, they may be administered by oral or inhalation routes, in an amount of 1 mg to 100 mg per time, from once a couple of days, once 3 days, once 2 days, once a day to a couple of times a day, in the case of an adult, or continuously administered by oral or inhalation routes from 1 to 24 hours a day. Since the dosage is affected by various conditions, an amount less than the above dosage may sometimes work well enough, or higher dosage may be required in some cases.
  • The compounds of the present invention may be administered in combination with other drugs for (1) complementation and/or enhancement of prevention and/or therapeutic efficacy of the preventive and/or therapeutic drug of the present invention, (2) dynamics, absorption improvement, dosage reduction of the preventive and/or therapeutic drug of the present invention, and/or (3) reduction of the side effects of the preventive and/or therapeutic drug of the present invention.
  • A concomitant medicine comprising the compounds of the present invention and other drug may be administered as a combination preparation in which both components are contained in a single formulation, or administered as separate formulations. The administration by separate formulations includes simultaneous administration and administration with some time intervals. In the case of the administration with some time intervals, the compound of the present invention can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present invention. The administration method of the respective drugs may be the same or different.
  • The dosage of the other drug can be properly selected, based on a dosage that has been clinically used. The compounding ratio of the compound of the present invention and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof. For example, the other drug may be used in an amount of 0.01 to 100 parts by mass, based on 1 part by mass of the compound of the present invention. The other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion. The other drug that complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention includes not only those that have already been discovered, but those that will be discovered in future, based on the above mechanism.
  • Diseases on which this concomitant use exerts a preventive and/or therapeutic effect are not particularly limited. The concomitant medicine can be used for any diseases, as long as it complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention.
  • The compound of the present invention can be used with an existing chemotherapeutic concomitantly or in a mixture form. Examples of the chemotherapeutic include an alkylation agent, nitrosourea agent, antimetabolite, anticancer antibiotics, vegetable-origin alkaloid, topoisomerase inhibitor, hormone drug, hormone antagonist, aromatase inhibitor, P-glycoprotein inhibitor, platinum complex derivative, other immunotherapeutic drugs and other anticancer drugs. Further, it can be used with a cancer treatment adjunct, such as a leucopenia (neutropenia) treatment drug, thrombocytopenia treatment drug, antiemetic and cancer pain intervention drug, concomitantly or in a mixture form.
  • In one embodiment, the compound(s) of the present invention can be used with other immunomodulators and/or a potentiating agent concomitantly or in a mixture form. Examples of the immunomodulator include various cytokines, vaccines and adjuvants. Examples of these cytokines, vaccines and adjuvants that stimulates immune responses include but not limited to GM-CSF, M-CSF, G-CSF, interferon-α, β, or γ, IL-1, IL-2, IL-3, IL-12, Poly (I:C) and CpG.
  • In another embodiment, the potentiating agents includes cyclophosphamide and analogs of cyclophosphamide, anti-TGFβ and Imatinib (Gleevac), a mitosis inhibitor, such as paclitaxel, Sunitinib (Sutent) or other antiangiogenic agents, an aromatase inhibitor, such as letrozole, an A2a adenosine receptor (A2AR) antagonist, an angiogenesis inhibitor, anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
  • As used herein, the term ‘compound(s)’ refers to the compounds disclosed in the present invention.
  • As used herein, the term “comprise” or “comprising” is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
  • As used herein, the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.
  • As used herein, the term “optionally substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: alkyl, alkoxy, acyl, halo, and hydroxyl. It is understood that the substituent may be further substituted.
  • As used herein the term “alkyl” refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, having from one to twenty carbon atoms (i.e., C1-20 alkyl) or one to ten carbon atoms (i.e., C1-10 alkyl) or one to five carbon atoms (i.e., C1-5 alkyl) and which is attached to the rest of the molecule by a single bond, e.g., including but not limited to methyl, ethyl, propyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • As used herein, the term “acyl” refers to RC(O)—, wherein R is alkyl as defined above. Examples of acyl group include, but are not limited to —C(O)CH3, —C(O)CH2CH3, —C(O)(CH2)2CH3, —C(O)(CH2)3CH3, —C(O)(CH2)4CH3, —C(O)(CH2)5CH3—C(O)(CH2)6CH3 and —C(O)(CH2)8CH3.
  • As used herein, the term “amidated C-terminus” refers to that the C-terminal of the amino acid in amide form.
  • As used herein, the term “amide form” refers to primary, secondary and/or tertiary amides and may be represented by the formula —C(O)NRxRy, wherein each of Rx and Ry independently represents hydrogen or alkyl.
  • As used herein, the term “amino” refers to —NH2 group. Unless set forth or recited to the contrary, all amino groups described or claimed herein may be substituted or unsubstituted.
  • As used herein, the term “amino acid” refers to amino acids having L or D stereochemistry at the alpha carbon. Optional substituent on amino acid means replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent, in case of amino acid containing hydroxyl group such as Serine or Threonine, the hydroxyl group can be substituted with the specified substituent.
  • As used herein, the term “aryl” refers to C4-C10 carbocyclic aromatic system containing one or two rings wherein such rings may be fused. Examples of aryl groups include, but are not limited to phenyl and naphthyl.
  • As used herein, the term “arylalkyl” refers to an aryl group as defined above directly bonded to an alkyl group (e.g., benzyl and the like).
  • As used herein, the term “carboxylic acid” refers to —COOH group.
  • As used herein, the term “coupling agent” means a compound that reacts with the hydroxyl moiety of a carboxy moiety thereby rendering it susceptible to nucleophilic attack. Coupling agents of this type are known in the art and include, but are not limited to, EDCI, HATU, HOBt, DIC and DCC.
  • As used herein the term “ester” refers to (C1-C6) linear or branched alkyl, (C4-C10)aryl, (C4-C10)heteroaryl or arylalkyl esters.
  • As used herein the term “esterified C-terminus” refers to that the C-terminal of the amino acid in ester form.
  • As used herein the term “free C-terminus’ refers to that the C-terminal of the amino acid in —CO2H form.
  • As used herein, the terms “halogen” or “halo” includes fluorine, chlorine, bromine or iodine.
  • As used herein the term “Hydroxy” or “Hydroxyl” refers to —OH group. “Pharmaceutically acceptable salt” is taken to mean an active ingredient, which comprises a compound of the formula (I) in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • The term “stereoisomer/stereoisomers” refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of formula (I), wherever they are chiral or when they bear one or more double bond. When the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis. In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).
  • The term “subject” includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • The phrase “therapeutically effective amount” or “efficient amount” refers to sufficient amount of the compound(s) of the present invention that (i) treats or prevents the particular disease, disorder or syndrome (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, disorder or syndrome or (iii) prevents or delays the onset of one or more symptoms of the particular disease, disorder or syndrome described herein. In the case of cancer, the therapeutically effective amount of the drug may decrease the number of cancer cells; decrease the cancer size; inhibit (i.e., slow to some extent and alternatively stop) cancer cell infiltration into peripheral organs; suppress (i.e., slow to some extent and alternatively stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. In the case of infectious disease states, the therapeutic effective amount is an amount sufficient to decrease or alleviate an infectious diseases, the symptoms of an infections caused by bacterial, viral and fungal.
  • Naturally-occurring amino acids are identified throughout the specification by the conventional three-letter abbreviations indicated in the below Table 2.
  • TABLE 2
    (Amino acid codes)
    Name 3-letter code
    Asparagine Asn
    Aspartic acid Asp
    Glutamic acid Glu
    Glutamine Gln
    Serine Ser
    Threonine Thr
  • The abbreviations used in the entire specification may be summarized herein below with their particular meaning.
  • ° C. (degree Celsius); 6 (delta); % (percentage); brine (NaCl solution); CDI CH2Cl2/DCM (Dichloromethane); DMF (Dimethyl formamide); DMSO (Dimethyl sulphoxide); DCC (Dicyclohexylcarbodiimide); DIC (N,N′-diisopropylcarbodiimide); DMSO-d6 (Deuterated DMSO); EDC.HCl/EDCI (1-(3-Dimethyl aminopropyl)-3-carbodiimide hydrochloride); Et2NH (Diethyl amine); EtOH (Ethanol); EtOAc (Ethyl acetate); ECF (ethylchloroformate); Fmoc (Fluorenylmethyloxycarbonyl chloride); g or gr (gram); H or H2 (Hydrogen); H2O (Water); HOBt/HOBT (1-Hydroxy benzotriazole); HCl (Hydrochloric acid); h or hr (Hours); HATU (2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uranium hexafluoro phosphate methanaminium); Hz (Hertz); HPLC (High-performance liquid chromatography); K2CO3 (Potassium carbonate); LiOH (Lithium hydroxide); LCMS (Liquid chromatography mass spectroscopy); mmol (Millimoles); M (Molar); μl (Micro litre); mL (Millilitre); mg (Milligram); m (Multiplet); MHz (Megahertz); MS (ES) (Mass spectroscopy-electro spray); min. (Minutes); Na (Sodium); NaHCO3 (Sodium bicarbonate); NaOAc (Sodium acetate); NMM (N-methyl morpholine); Na2SO4 (Sodium sulphate); N2 (Nitrogen); NMR (Nuclear magnetic resonance spectroscopy); NH3 (Ammonia); NH2OH.HCl (Hydroxylamine hydrochloride; PD-L1 (Programmed death-ligand 1); PD-L2 (Programmed cell death 1 ligand 2); prep-HPLC/preparative HPLC (Preparative High-performance liquid chromatography); S (Singlet); tBu (tertiary butyl); TEA/Et3N (Triethyl amine); TFA (Trifluoroaceticacid); TFAA (Trifluroacetic anhydride); TLC (Thin Layer Chromatography); THF (Tetrahydrofuran); TIPS (Triisopropylsilane); TFA/CF3COOH (Trifluoroacetic acid); t (Triplet); tR, (Retention time); Trt (Triphenyl methane); etc.
  • An embodiment of the present invention provides the preparation of compounds of formula (I) according to the procedures of the following examples, using appropriate materials. Those skilled in the art will understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. Moreover, by utilizing the procedures described in detail, one of ordinary skill in the art can prepare additional compounds of the present invention.
  • The starting materials are generally available from commercial sources such as Sigma-Aldrich, USA or Germany; Chem-Impex USA; G.L. Biochem, China and Spectrochem, India.
    • Purification and Characterization of Compounds
  • Analytical HPLC method: Analytical HPLC was performed using on ZIC HILIC 200 A° column (4.6 mm×250 mm, 5 μm), Flow rate: 1.0 mL/min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate, Buffer B: Acetonitrile, Equilibration of the column with 90% buffer B and elution by a gradient of 90% to 40% buffer B during 30 min.
  • Preparative HPLC Method: Preparative HPLC was performed using on SeQuant ZIC HILIC 200 A° column (10 mm×250 mm, 5 μm), Flow rate: 5.0 mL/min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate (adjust to pH-4 with Acetic Acid), Buffer B: Acetonitrile, Equilibration of the column with 90% buffer B and elution by a gradient of 90% to 40% buffer B during 20 min.
  • LCMS was performed on AP1 2000 LC/MS/MS triple quad (Applied bio systems) with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Agilent LC/MSD VL single quad with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Shimadzu LCMS 2020 single quad with Prominence UFLC system with SPD-20 A DAD.
    • Example 1 Synthesis of Compound 1
  • Figure US20150073024A1-20150312-C00030
  • FIG. 1A illustrates Steps 1a, 1b and 1c.
  • Step 1a: Ethylchloroformate (1.5 g, 13.78 mmol) and N-Methylmorpholine (1.4 g, 13.78 mmol) were added to a solution of compound 1a (3 g, 11.48 mmol) in THF (30 mL) and stirred at −20° C. After 20 min. liquid ammonia (0.77 g, 45.92 mmol) was added to the active mixed anhydride formed in-situ and stirred at 0-5° C. for 20 min. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with NaHCO3, citric acid, brine solution, dried over Na2SO4 and evaporated under reduced pressure to get 2.9 g of compound 1b (Yield: 96.3%). LCMS: 261.0 (M+H)+.
  • Step 1 b: Trifluroacetic anhydride (9.7 g, 46.0 mmol) was added to a solution of compound 1b (8 g, 30.7 mmol) in pyridine (24.3 g, 307.0 mmol) and stirred at room temperature for 3 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with NaHCO3, citric acid, brine solution, dried over Na2SO4 and evaporated under reduced pressure to afford 7 g of compound 1c (Yield: 94.0%). LCMS: 187.2 (M-′Bu)+.
  • Step 1c: Hydroxylamine hydrochloride (3 g, 43.37 mmol) and potassium carbonate (6 g, 43.37 mmol) were added to a solution of compound 1c (7 g, 28.01 mmol) in EtOH (70 mL) and stirred at 90° C. for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with brine solution, dried over Na2SO4 and evaporated under reduced pressure. The crude compound was purified by silica gel column chromatography (Eluent: 0-5% ethyl acetate in hexane) to get 4.2 g of compound 1d (Yield: 52.8%). LCMS: 276.4 (M+H)+.
  • Step 1d: Deoxo-Fluor® (1.83 g, 8.3 mmol) was added to a solution of Fmoc-Asn(Trt)-OH (4.5 g, 7.5 mmol) in CH2Cl2 (50 mL) and stirred at 0° C. for 3 h. Then CH2Cl2 was evaporated and triturated with hexane, decanted and evaporated under vacuum to get the corresponding acid fluoride. NMM (1.17 g, 11.6 mmol) and compound 1d (1.6 g, 5.8 mmol) in THF were added to the acid fluoride and stirred at room temperature for 12 h. Then THF was evaporated and sodium acetate (0.72 g, 8.7 mmol) was added followed by EtOH (50 mL). The reaction mixture was stirred at 90° C. for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure and partitioned between water and ethyl acetate. Organic layer was washed with NaHCO3, citric acid, brine solution, dried over Na2SO4 and evaporated under reduced pressure, which was further purified by silica gel column chromatography (Eluent: 0-5% ethyl acetate in hexane) to afford 2.8 g of compound 1e (Yield: 44.4%). LCMS: 836.4 (M+H)+.
  • Step 1e: To compound 1e (2.3 g, 2.7 mmol) in CH2Cl2 (10 mL) diethylamine (10 mL) was added and the reaction mixture was stirred at room temperature for 30 min. The resulting solution was concentrated in vacuum to get gummy residue. The crude compound was purified by neutral alumina column chromatography (Eluent: 0-50% ethyl acetate in hexane then 0-5% methanol in chloroform) to get 1.4 g of 1f (Yield: 90%). LCMS: 636.5 (M+Na)+.
  • Step 1f: To a solution of compound 1f (0.45 g) in CH2Cl2 (5 mL), trifluoroacetic acid (5 mL) and catalytic amount of triisopropylsilane were added and stirred for 3 h at room temperature to remove the acid sensitive protecting groups. The resulting solution was concentrated in vacuum to afford 0.29 g of crude compound 1 which was purified using prep-HPLC method described under experimental conditions. 1H NMR (DMSO-d6, 400 MHz): δ 2.58 (m, 2H), 3.53 (m, 3H), 3.91 (t, 1H), 4.36 (t, 1H), 6.91 (s, 1H), 7.45 (s, 1H); 13C NMR (DMSO-d6, 400 MHz): δ 20.85, 45.71, 50.23, 65.55, 171.03, 171.41, 181.66. LCMS: 216.2 (M+H)+; HPLC: tR=13.1 min.
    • Example 2 Synthesis of Compound 2
  • Figure US20150073024A1-20150312-C00031
  • FIG. 2 illustrates Steps 2a and 2b.
  • Step 2a: The urea linkage was carried out by the coupling compound 1f (2.7 g, 4.39 mmol) in THF (30 mL) at room temperature with compound 2b (1.67 g, 4.39 mmol). The coupling was initiated by the addition of TEA (0.9 g, 8.78 mmol) in THF (10 m L) and the resultant mixture was stirred at room temperature. After completion of 20 h, THF was evaporated from the reaction mass, and partitioned between water and ethyl acetate. Organic layer was washed with water, brine, dried over Na2SO4 and evaporated under reduced pressure to get compound 2a, which was further purified by silica gel column chromatography (Eluent: 0-50% ethyl acetate in hexane) to afford 3.46 g of compound 2a (Yield: 92.10%). LCMS 857.4 (M+H)+.
  • Step 2b: To a solution of compound 2a (0.22 g, 0.25 mmol) in CH2Cl2 (5 m L), trifluoroacetic acid (5 mL) and catalytic amount of triisopropylsilane were added and stirred for 3 h at room temperature. The resulting solution was concentrated under reduced pressure to obtain 0.35 g of crude compound. The crude solid material was purified using preparative-HPLC method described under experimental conditions. LCMS: 347.1 (M+H)+; HPLC: tR=12.9 min.
    • Synthesis of Compound 2b (NO2—C6H4—OCO-Thr (OtBu)-OtBu)
  • To the compound H-Ser(tBu)-OtBu (2 g, 9.2 mmol) in CH2Cl2 (20 mL), triethylamine (1.39 g, 13.8 mmol) was added and the solution was stirred at room temperature for 5-10 min. To this mixture, solution of 4-Nitrophenyl chloroformate (2.22 g, 11.04 mmol) in CH2Cl2 was added and the resultant mixture was stirred at room temperature for 30 min. The completion of the reaction was confirmed by TLC analysis. After completion of reaction, reaction mixture was diluted with CH2Cl2 and washed with water and 5.0 M citric acid solution, dried over Na2SO4 and evaporated under reduced pressure to get crude compound 2b, which was further purified by silica gel column chromatography (Eluent: 0-20% ethyl acetate in hexane) to yield 2.1 g (58.9%) of 2b.
    • Example 3 Synthesis of Compound 3
  • Figure US20150073024A1-20150312-C00032
  • The compound was synthesised using similar procedure as depicted in Example 1 (compound 1) and D-amino acids are linked up in reverse order. Boc-D-Thr(tBu)-OH was used in place of Boc-Ser(tBu)-OH (compound 1a, Example 1) and Fmoc-D-Asn(trt)-OH in place of Fmoc-Asn(trt)-OH to yield 0.15 g crude material of the title compound 3. LCMS: 230.1 (M+H)+.
    • Example 4 Synthesis of Compound 4
  • Figure US20150073024A1-20150312-C00033
  • The compound was synthesised using similar procedure as depicted in Example 2 for synthesising compound 2 using H-Thr(tBu)-OtBu instead of H-Ser(tBu)-OtBu (in synthesis of compound 2b) to yield 0.35 g crude material of the title compound. The crude solid material was purified using preparative HPLC described under experimental conditions. LCMS: 361.2 (M+H)+, HPLC: tR=12.19 min.
    • Example 5 Synthesis of Compound 5
  • Figure US20150073024A1-20150312-C00034
  • The compound was synthesised using similar procedure as depicted in Example 4 (compound 4) using D-amino acids are linked up in reverse order. Boc-D-Thr(tBu)-OH was used in place of Boc-Ser(tBu)-OH, Fmoc-D-Asn(trt)-OH in place of Fmoc-Asn(trt)-OH and H-D-Ser(tBu)-OtBu was used in place of H-Thr(tBu)-OtBu to yield 0.3 g crude material of the title compound. The crude solid material was purified using preparative HPLC described under experimental conditions. LCMS: 361.3 (M+H)+. HPLC: tR=13.58 min.
    • Example 6 Synthesis of Compound 6
  • Figure US20150073024A1-20150312-C00035
  • The compound was synthesised using similar procedure as depicted in Example 2 by using H-Thr(tBu)-OMe instead of H-Ser(tBu)-OtBu (in synthesis of compound 2b) to yield 0.2 g crude material of the title compound. The crude solid material was purified using preparative HPLC described under experimental conditions. LCMS: 375.1 (M+H)+, HPLC: tR=11.84 min.
    • Example 7 Synthesis of Compound 7
  • Figure US20150073024A1-20150312-C00036
  • FIG. 3 illustrates Steps 7a, 7b and 7c.
  • Step 7a: The compound 7a was synthesised using similar procedure as for compound 2a (Example 2, step 2a) using H-Thr(tBu)-OMe instead of H-Ser(tBu)-OtBu to get crude material which was further purified by silica gel column chromatography (Eluent: 0-50% ethyl acetate in hexane) to get 2.0 g of compound 7a (Yield: 74%). LCMS: 829.2 (M+H)+.
  • Step 7b: To a solution of compound 7a (0.35 g, 4.0 mmol) in THF (5 mL) was added lithium hydroxide (0.026 g, 0.63 mmol) at 0° C. and the mixture was stirred for 2 h at room temperature. The completion of the reaction was confirmed by TLC analysis. THF was evaporated from the reaction mass, and partitioned between water and ethyl acetate. Organic layer was washed with citric acid, brine solution, dried over Na2SO4 and evaporated under reduced pressure to afford 7b, which was further purified by silica gel column chromatography (Eluent: 0-5% methanol in DCM) to get 0.3 g of product 7b (Yield: 86.7%). LCMS 815.2 (M+H)+.
  • Step 7c: Compound 7b (0.295 g, 0.39 mmol) was anchored to Rink amide resin (0.7 g, 0.55 mmol/g) using HOBT (0.072 g, 0.54 mmol) and DIC (0.068 g, 0.54 mmol) method in DMF (10 mL). The resin was stirred for 12 h at room temperature. The resin was washed with DCM, DMF and DCM and dried. The target compound was cleaved from the rink amide resin using TFA (5 mL) and catalytic amount of TIPS. The resin was allowed to remain at room temperature for 2 h with occasional stirring. After 2 h, TFA and TIPS were evaporated under nitrogen atmosphere and the resulting residue was washed with diethyl ether to yield 0.1 g crude material of the title compound 7. The crude solid material was purified using preparative HPLC described under experimental conditions. LCMS: 360.0 (M+H)+, HPLC: tR=13.88 min.
    • Example 8 Synthesis of Compound 8
  • Figure US20150073024A1-20150312-C00037
  • The compound was synthesised using similar procedure as depicted in Example 2 (compound 2) using Fmoc-Glu(OtBu)-OH instead of Fmoc-Asn(Trt)-OH to get 0.4 g crude material of the title compound. The crude solid material was purified using preparative HPLC described under experimental conditions. LCMS: 362.1 (M+H)+. HPLC: tR=13.27 min.
  • The compounds in Table 3 below were prepared based on the experimental procedures described above.
  • TABLE 3
    Compound LCMS HPLC
    No. Structure (M + H)+ (tR in min.)
    9
    Figure US20150073024A1-20150312-C00038
         		431.1 4.64
    10
    Figure US20150073024A1-20150312-C00039
         		375.2 11.13
    11
    Figure US20150073024A1-20150312-C00040
         		361.2 11.85
    12
    Figure US20150073024A1-20150312-C00041
         		361.2 12.38
    13
    Figure US20150073024A1-20150312-C00042
         		361.2 12.02
    14
    Figure US20150073024A1-20150312-C00043
         		375.1 11.74
    15
    Figure US20150073024A1-20150312-C00044
         		361.1 12.41
    16
    Figure US20150073024A1-20150312-C00045
         		361.1 12.34
    17
    Figure US20150073024A1-20150312-C00046
         		361.2 12.62
    18
    Figure US20150073024A1-20150312-C00047
         		361.2 12.87
    19
    Figure US20150073024A1-20150312-C00048
         		376.1 12.41
    20
    Figure US20150073024A1-20150312-C00049
         		375.1 12.31
    21
    Figure US20150073024A1-20150312-C00050
         		361.3 13.19
    22
    Figure US20150073024A1-20150312-C00051
         		375.1 12.52
    23
    Figure US20150073024A1-20150312-C00052
         		389.2 12.07
    24
    Figure US20150073024A1-20150312-C00053
         		362.2 12.78
    25
    Figure US20150073024A1-20150312-C00054
         		348.2 13.21
    • Example 9 Rescue of Mouse Splenocyte Proliferation in Presence of Recombinant PD-L1/PD-L2
  • Recombinant mouse PD-L1 (rm-PDL-1, cat no: 1019-B7-100 & rh-PDL-1, cat no: 156-B7-100, R&D Systems) were used as the source of PD-L1.
    • Requirement
  • Mouse splenocytes harvested from 6-8 weeks old C57 BL6 mice; RPMI 1640 (GIBCO, Cat #11875); DMEM with high glucose (GIBCO, Cat # D6429); Fetal Bovine Serum [Hyclone, Cat # SH30071.03]; Penicillin (10000 unit/mL)-Streptomycin(10,000 μg/mL) Liquid (GIBCO, Cat #15140-122); MEM Sodium Pyruvate solution 100 mM (100×), Liquid (GIBCO, Cat #11360); Nonessential amino acid (GIBCO, Cat #11140); L-Glutamine (GIBCO, Cat #25030); Anti-CD3 antibody (eBiosciences—16-0032); Anti-CD28 antibody (eBiosciences—16-0281); ACK lysis buffer (1 mL) (GIBCO, Cat #-A10492); Histopaque (density-1.083 gm/mL) (SIGMA 10831); Trypan blue solution (SIGMA-T8154); 2 mL Norm Ject Luer Lock syringe-(Sigma 2014-12); 40 μm nylon cell strainer (BD FALCON 35230); Hemacytometer (Bright line-SIGMA Z359629); FACS Buffer (PBS/0.1% BSA): Phosphate Buffered Saline (PBS) pH 7.2 (HiMedia TS1006) with 0.1% Bovine Serum Albumin (BSA) (SIGMA A7050) and sodium azide (SIGMA 08591); 5 mM stock solution of CFSE: CFSE stock solution was prepared by diluting lyophilized CFSE with 180 μL of Dimethyl sulfoxide (DMSO C2H6SO, SIGMA-D-5879) and aliquoted in to tubes for further use. Working concentrations were titrated from 10 μM to 1 μM. (eBioscience-650850-85); 0.05% Trypsin and 0.02% EDTA (SIGMA 59417C); 96-well format ELISA plates (Corning CLS3390); BD FACS caliber (E6016); Recombinant mouse B7-H1/PDL1 Fc Chimera, (rm-PD-L1 cat no: 1019-B7-100).
    • Protocol Splenocyte Preparation and Culturing:
  • Splenocytes harvested in a 50 mL falcon tube by mashing mouse spleen in a 40 μm cell strainer were further treated with 1 mL ACK lysis buffer for 5 min at room temperature. After washing with 9 mL of RPMI complete media, cells were re-suspended in 3 mL of 1×PBS in a 15 mL tube. 3 mL of Histopaque was added carefully to the bottom of the tube without disturbing overlaying splenocyte suspension. After centrifuging at 800×g for 20 min at room temperature, the opaque layer of splenocytes was collected carefully without disturbing/mixing the layers. Splenocytes were washed twice with cold 1×PBS followed by total cell counting using Trypan Blue exclusion method and used further for cell based assays.
  • Splenocytes were cultured in RPMI complete media (RPMI+10% fetal bovine serum+1 mM sodium pyruvate+10,000 units/mL penicillin and 10,000 μg/mL streptomycin) and maintained in a CO2 incubator with 5% CO2 at 37° C.
    • CFSE Proliferation Assay:
  • CFSE is a dye that passively diffuses into cells and binds to intracellular proteins. 1×106 cells/mL of harvested splenocytes were treated with 5 μM of CFSE in pre-warmed 1×PBS/0.1% BSA solution for 10 min at 37° C. Excess CFSE was quenched using 5 volumes of ice-cold culture media to the cells and incubated on ice for 5 min. CFSE labelled splenocytes were further given three washes with ice cold complete RPMI media. CFSE labelled 1×105 splenocytes added to wells containing either MDA-MB231 cells (1×105 cells cultured in high glucose DMEM medium) or recombinant human PDL-1 (100 ng/mL) and test compounds. Splenocytes were stimulated with anti-mouse CD3 and anti-mouse CD28 antibody (1 μg/mL each), and the culture was further incubated for 72 h at 37° C. with 5% CO2. Cells were harvested and washed thrice with ice cold FACS buffer and % proliferation was analyzed by flow cytometry with 488 nm excitation and 521 nm emission filters.
    • Data Compilation, Processing and Inference:
  • Percent splenocyte proliferation was analyzed using cell quest FACS program and percent rescue of splenocyte proliferation by compound was estimated after deduction of % background proliferation value and normalising to % stimulated splenocyte proliferation (positive control) as 100%.
  • Stimulated splenocytes: Splenocytes+anti-CD3/CD28 stimulation
    Background proliferation: Splenocytes+anti-CD3/CD28+PD-L1
    Compound proliferation: Splenocytes+anti-CD3/CD28+PD-L1+Compound
    Compound effect is examined by adding required conc. of compound to anti-CD3/CD28 stimulated splenocytes in presence of ligand (PDL-1) (Table 4).
  • TABLE 4
    Percent rescue of splenocyte
    Compound proliferation @ 100 nM
    No. compound concentration
    1 93
    2 50
    4 89
    5 67.6
    6 84
    7 55
    8 67
    9 34
    10 49
    11 90
    12 64
    13 74
    14 75
    15 83
    16 72
    17 55
    18 64
    19 88
    20 69
    21 47
    22 55
    23 74
    24 52
    25 91

Claims (20)

What is claimed is:
1. A compound of formula (I)
Figure US20150073024A1-20150312-C00055
wherein,
Q is S or O;
R1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
R2 is hydrogen or —CO-Aaa;
Aaa is an amino acid residue Thr or Ser; wherein a C-terminus thereof is a free terminus, is amidated or is esterified;
R3 is a side chain of amino acid Asn, Asp, Gln, or Glu;
----- is an optional bond;
R4 and R5 independently are hydrogen or absent;
R6 is hydrogen, alkyl or acyl;
or a pharmaceutically acceptable salt or a stereoisomer thereof.
2. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (IA):
Figure US20150073024A1-20150312-C00056
or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
R1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl;
R3 is a side chain of amino acid Asn, Asp, Gln, or Glu; and
Aaa is an amino acid residue Thr or Ser; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.
3. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (IB):
Figure US20150073024A1-20150312-C00057
or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
R1 is a side chain of amino acid Ser or Thr, optionally substituted with alkyl or acyl; and
R3 is a side chain of amino acid Asn, Asp, Gln, or Glu.
4. The compound according to claim 1, wherein
R1 is a side chain of amino acid residue Ser or Thr;
R2 is —CO-Aaa;
Aaa is an amino acid residue Thr or Ser; wherein the C-terminus is free; and
R3 is a side chain of amino acid residue Asn or Glu.
5. The compound according to claim 1, wherein Q is O.
6. The compound according to claim 1, wherein R6 is —C(O)CH3, —C(O)CH2CH3, —C(O)(CH2)2CH3, —C(O)(CH2)3CH3, —C(O)(CH2)4CH3 or —C(O)(CH2)5CH3.
7. The compound according to claim 1, wherein the compound of formula (I) has a structure selected from the group consisting of
Compound No. Structure 1.
Figure US20150073024A1-20150312-C00058
 2.
Figure US20150073024A1-20150312-C00059
 3.
Figure US20150073024A1-20150312-C00060
 4.
Figure US20150073024A1-20150312-C00061
 5.
Figure US20150073024A1-20150312-C00062
 6.
Figure US20150073024A1-20150312-C00063
 7.
Figure US20150073024A1-20150312-C00064
 8.
Figure US20150073024A1-20150312-C00065
 9.
Figure US20150073024A1-20150312-C00066
 10.
Figure US20150073024A1-20150312-C00067
 11.
Figure US20150073024A1-20150312-C00068
 12.
Figure US20150073024A1-20150312-C00069
 13.
Figure US20150073024A1-20150312-C00070
 14.
Figure US20150073024A1-20150312-C00071
 15.
Figure US20150073024A1-20150312-C00072
 16.
Figure US20150073024A1-20150312-C00073
 17.
Figure US20150073024A1-20150312-C00074
 18.
Figure US20150073024A1-20150312-C00075
 19.
Figure US20150073024A1-20150312-C00076
 20.
Figure US20150073024A1-20150312-C00077
 21.
Figure US20150073024A1-20150312-C00078
 22.
Figure US20150073024A1-20150312-C00079
 23.
Figure US20150073024A1-20150312-C00080
 24.
Figure US20150073024A1-20150312-C00081
 25.
Figure US20150073024A1-20150312-C00082
or a pharmaceutically acceptable salt or a stereoisomer thereof.
8. A pharmaceutical composition comprising at least one compound according to claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.
9. The pharmaceutical composition according to claim 8 further comprising at least one of an anticancer agent, chemotherapy agent, or antiproliferative compound.
10. A method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.
11. A method of inhibiting growth of tumour cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.
12. The method of claim 11, wherein the tumour cells are from a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, melanoma, prostate cancer, and renal cancer.
13. The method of claim 11, wherein the tumour cells are from a cancer selected from the group consisting of bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hogkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or reter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.
14. A method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.
15. A method of treating bacterial, viral and fungal infections in a subject comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.
16. A compound having a structural formula selected from the group consisting of
Compound No. Structure 1
Figure US20150073024A1-20150312-C00083
 2
Figure US20150073024A1-20150312-C00084
 3
Figure US20150073024A1-20150312-C00085
 4
Figure US20150073024A1-20150312-C00086
 5
Figure US20150073024A1-20150312-C00087
 6
Figure US20150073024A1-20150312-C00088
 7
Figure US20150073024A1-20150312-C00089
 8
Figure US20150073024A1-20150312-C00090
 9
Figure US20150073024A1-20150312-C00091
 10
Figure US20150073024A1-20150312-C00092
 11
Figure US20150073024A1-20150312-C00093
 12
Figure US20150073024A1-20150312-C00094
 13
Figure US20150073024A1-20150312-C00095
 14
Figure US20150073024A1-20150312-C00096
 15
Figure US20150073024A1-20150312-C00097
 16
Figure US20150073024A1-20150312-C00098
 17
Figure US20150073024A1-20150312-C00099
 18
Figure US20150073024A1-20150312-C00100
 19
Figure US20150073024A1-20150312-C00101
 20
Figure US20150073024A1-20150312-C00102
 21
Figure US20150073024A1-20150312-C00103
 22
Figure US20150073024A1-20150312-C00104
 23
Figure US20150073024A1-20150312-C00105
 24
Figure US20150073024A1-20150312-C00106
 25
Figure US20150073024A1-20150312-C00107
or a pharmaceutically acceptable salt or a stereoisomer thereof.
17. A pharmaceutical composition comprising at least one of the compounds according to claim 16 and a pharmaceutically acceptable carrier or excipient.
18. A method for treating a cancer or infectious disease, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 17.
19. The method according to claim 18, wherein the cancer is breast cancer, colon cancer, lung cancer, melanoma, prostate cancer, or renal cancer.
20. The method according to claim 18, wherein the infectious disease is a bacterial infectious disease, a viral infectious disease or a fungal infectious disease.
US14/478,759 2013-09-06 2014-09-05 1,2,4-Oxadiazole Derivatives as Immunomodulators Abandoned US20150073024A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US15/298,539 US9771338B2 (en) 2013-09-06 2016-10-20 1,2,4-oxadiazole derivatives as immunomodulators
US15/713,671 US10173989B2 (en) 2013-09-06 2017-09-24 1,2,4-oxadiazole derivatives as immunomodulators
US16/192,030 US10590093B2 (en) 2013-09-06 2018-11-15 1,2,4-oxadiazole derivatives as immunomodulators
US16/806,872 US10961205B2 (en) 2013-09-06 2020-03-02 1,2,4-oxadiazole derivatives as immunomodulators
US17/192,279 US11512060B2 (en) 2013-09-06 2021-03-04 1,2,4-oxadiazole derivatives as immunomodulators
US17/981,695 US12037321B2 (en) 2013-09-06 2022-11-07 1,2,4-oxadiazole derivatives as immunomodulators
US18/747,813 US20240400525A1 (en) 2013-09-06 2024-06-19 1,2,4-Oxadiazole Derivatives as Immunomodulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4011CH2013 2013-09-06
IN4011/CHE/2013 2013-09-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/298,539 Continuation US9771338B2 (en) 2013-09-06 2016-10-20 1,2,4-oxadiazole derivatives as immunomodulators

Publications (1)

Publication Number Publication Date
US20150073024A1 true US20150073024A1 (en) 2015-03-12

Family

ID=51830558

Family Applications (9)

Application Number Title Priority Date Filing Date
US14/478,806 Expired - Fee Related US9233940B2 (en) 2013-09-06 2014-09-05 Cyclic peptidomimetic compounds as immunomodulators
US14/478,759 Abandoned US20150073024A1 (en) 2013-09-06 2014-09-05 1,2,4-Oxadiazole Derivatives as Immunomodulators
US15/298,539 Active US9771338B2 (en) 2013-09-06 2016-10-20 1,2,4-oxadiazole derivatives as immunomodulators
US15/713,671 Active US10173989B2 (en) 2013-09-06 2017-09-24 1,2,4-oxadiazole derivatives as immunomodulators
US16/192,030 Active US10590093B2 (en) 2013-09-06 2018-11-15 1,2,4-oxadiazole derivatives as immunomodulators
US16/806,872 Active US10961205B2 (en) 2013-09-06 2020-03-02 1,2,4-oxadiazole derivatives as immunomodulators
US17/192,279 Active US11512060B2 (en) 2013-09-06 2021-03-04 1,2,4-oxadiazole derivatives as immunomodulators
US17/981,695 Active US12037321B2 (en) 2013-09-06 2022-11-07 1,2,4-oxadiazole derivatives as immunomodulators
US18/747,813 Pending US20240400525A1 (en) 2013-09-06 2024-06-19 1,2,4-Oxadiazole Derivatives as Immunomodulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/478,806 Expired - Fee Related US9233940B2 (en) 2013-09-06 2014-09-05 Cyclic peptidomimetic compounds as immunomodulators

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/298,539 Active US9771338B2 (en) 2013-09-06 2016-10-20 1,2,4-oxadiazole derivatives as immunomodulators
US15/713,671 Active US10173989B2 (en) 2013-09-06 2017-09-24 1,2,4-oxadiazole derivatives as immunomodulators
US16/192,030 Active US10590093B2 (en) 2013-09-06 2018-11-15 1,2,4-oxadiazole derivatives as immunomodulators
US16/806,872 Active US10961205B2 (en) 2013-09-06 2020-03-02 1,2,4-oxadiazole derivatives as immunomodulators
US17/192,279 Active US11512060B2 (en) 2013-09-06 2021-03-04 1,2,4-oxadiazole derivatives as immunomodulators
US17/981,695 Active US12037321B2 (en) 2013-09-06 2022-11-07 1,2,4-oxadiazole derivatives as immunomodulators
US18/747,813 Pending US20240400525A1 (en) 2013-09-06 2024-06-19 1,2,4-Oxadiazole Derivatives as Immunomodulators

Country Status (29)

Country Link
US (9) US9233940B2 (en)
EP (2) EP3041827B1 (en)
JP (1) JP6521977B2 (en)
KR (1) KR102362277B1 (en)
CN (2) CN108164474B (en)
AU (5) AU2014316682B2 (en)
BR (1) BR112016004889B1 (en)
CA (1) CA2922607C (en)
CU (1) CU24362B1 (en)
CY (2) CY1120899T1 (en)
DK (2) DK3363790T3 (en)
EA (1) EA030155B1 (en)
ES (2) ES2788848T3 (en)
HR (2) HRP20181052T1 (en)
HU (2) HUE048874T2 (en)
IL (3) IL244314A (en)
LT (2) LT3041827T (en)
MX (1) MX365218B (en)
MY (1) MY186438A (en)
PH (1) PH12016500406A1 (en)
PL (2) PL3041827T3 (en)
PT (2) PT3363790T (en)
RS (2) RS60317B1 (en)
SG (1) SG11201601682RA (en)
SI (2) SI3041827T1 (en)
SM (2) SMT202000283T1 (en)
TR (1) TR201809838T4 (en)
WO (1) WO2015033299A1 (en)
ZA (1) ZA201602193B (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170101386A1 (en) * 2013-09-06 2017-04-13 Aurigene Discovery Technologies Limited 1,2,4-Oxadiazole Derivatives as Immunomodulators
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
WO2017205464A1 (en) * 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) * 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018100556A1 (en) 2016-12-02 2018-06-07 Augusta University Research Institute, Inc. Compositions for modulating pd-1 signal transduction
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2019087087A1 (en) * 2017-11-03 2019-05-09 Aurigene Discovery Technologies Limited Dual inhibitors of tim-3 and pd-1 pathways
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10415015B2 (en) 2016-10-31 2019-09-17 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
US10568870B2 (en) 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020096682A2 (en) 2018-08-31 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US10744118B2 (en) 2012-12-07 2020-08-18 Chemocentryx, Inc. Diazole lactams
US10781189B2 (en) * 2015-03-10 2020-09-22 Aurigene Discovery Technologies Limited 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3747472A1 (en) 2015-09-15 2020-12-09 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11040948B2 (en) * 2017-09-29 2021-06-22 Curis, Inc. Crystal forms of immunomodulators
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2022094567A1 (en) 2020-10-28 2022-05-05 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11680051B2 (en) 2017-10-11 2023-06-20 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11981921B2 (en) 2022-04-15 2024-05-14 Iovance Biotherapeutics, Inc. TIL expansion processes using specific cytokine combinations and/or AKTi treatment
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
US12064418B2 (en) 2017-11-06 2024-08-20 Curis, Inc. Conjoint therapies for immunomodulation

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11265444B2 (en) 2013-08-23 2022-03-01 Preemadonna Inc. Apparatus for applying coating to nails
US9687059B2 (en) 2013-08-23 2017-06-27 Preemadonna Inc. Nail decorating apparatus
SI3041828T1 (en) 2013-09-06 2018-10-30 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
CU20170118A7 (en) * 2015-03-10 2018-02-08 Aurigene Discovery Tech Ltd TIADIAZOL AND 1,2,4-OXADIAZOL 3-SUBSTITUTED COMPOUNDS AS IMMUNOMODULATORS
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
JP7185532B2 (en) 2016-06-27 2022-12-07 ケモセントリックス，インコーポレイティド immunomodulatory compounds
KR102482673B1 (en) 2016-07-05 2022-12-30 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. Aromatic acetylenic or aromatic ethylenic compounds, their intermediates, manufacturing methods, drug compositions and uses
AR109180A1 (en) 2016-07-28 2018-11-07 Idorsia Pharmaceuticals Ltd PIPERIDINE DERIVATIVES AS RECEIVER MODULATORS CXCL11 / CXCL12 CXCR7
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018051254A1 (en) * 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
CA3040143A1 (en) 2016-10-14 2018-04-19 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
CN110139856A (en) * 2016-10-20 2019-08-16 奥列基因发现技术有限公司 The double inhibitor of VISTA and PD-1 access
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
ES2988845T3 (en) 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Predictive and diagnostic procedures for prostate cancer
CN108395443B (en) * 2017-02-04 2021-05-04 广州丹康医药生物有限公司 Cyclic compounds inhibiting programmed death receptor ligand 1 and uses thereof
TW201841896A (en) * 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 Heterocyclic compound serving as pd-l1 inhibitor
CN108863963B (en) * 2017-05-08 2022-05-27 南京圣和药物研发有限公司 Heterocyclic compounds as PD-L1 inhibitors
AR111807A1 (en) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd BENZOFURAN AND BENZOTIOPHENE DERIVATIVES AS MODULATORS OF THE PGE2 RECEIVER
SG11201908660RA (en) 2017-05-18 2019-10-30 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
KR102626982B1 (en) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pyrimidine derivatives as PGE2 receptor modulators
JP7253500B2 (en) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド pyrimidine derivative
SI3625222T1 (en) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
CN109096219B (en) * 2017-06-20 2023-03-21 广州丹康医药生物有限公司 Novel anti-PD-L1 compound, application thereof and composition containing same
EP3658522B1 (en) 2017-07-28 2021-12-22 ChemoCentryx, Inc. Immunomodulator compounds
CA3071951A1 (en) 2017-08-08 2019-02-14 Chemocentryx, Inc. Macrocyclic immunomodulators
TW201920202A (en) 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019070886A1 (en) 2017-10-04 2019-04-11 Preemadonna Inc. Systems and methods of adaptive nail printing and collaborative beauty platform hosting
ES2984919T3 (en) 2017-11-06 2024-10-31 Hoffmann La Roche Diagnostic and therapeutic procedures for cancer
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7098748B2 (en) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． 2'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN109988144B (en) 2017-12-29 2024-07-05 广州再极医药科技有限公司 Aromatic vinyl or aromatic ethyl derivative, preparation method, intermediate, pharmaceutical composition and application thereof
EP3737684B1 (en) 2018-01-10 2022-11-16 Idorsia Pharmaceuticals Ltd 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
EA202091267A1 (en) 2018-01-12 2020-11-03 Ориджен Дискавери Текнолоджис Лимитед 1,2,4-OXADIAZOLIC COMPOUNDS AS INHIBITORS OF CD47 SIGNAL PATHWAYS
JP7217279B2 (en) 2018-01-15 2023-02-02 イドーシア ファーマシューティカルズ リミテッド Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CA3087784A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
CN111615513A (en) 2018-01-19 2020-09-01 爱杜西亚药品有限公司 C5a receptor modulators
AU2019212888B8 (en) 2018-01-26 2024-01-04 Idorsia Pharmaceuticals Ltd Crystalline forms of the CXCR7 receptor antagonist (3s,4s)-1- cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
CN118084940A (en) 2018-02-13 2024-05-28 吉利德科学公司 PD-1/PD-L1 inhibitors
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. Indane-amines as pd-l1 antagonists
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN112218658A (en) 2018-03-12 2021-01-12 国家健康科学研究所 Use of caloric restriction mimetics for enhancing chemoimmunotherapy for cancer treatment
WO2019175799A2 (en) * 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
TW201945388A (en) 2018-04-12 2019-12-01 美商精密生物科學公司 Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
KR20210024550A (en) 2018-06-23 2021-03-05 제넨테크, 인크. PD-1 axis binding antagonist, platinum agent, and method of treating lung cancer using topoisomerase II inhibitor
KR102625712B1 (en) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 PD-1/PD-L1 inhibitors
IL280107B2 (en) 2018-07-18 2024-12-01 Genentech Inc Atezolizumab for use in the treatment of non-squamous non-small cell lung cancer (NCSLS) and kits containing atezolizumab
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
CN111057069B (en) * 2018-10-16 2024-01-26 武汉光谷通用名药物研究院有限公司 Cyclic compound, application and composition thereof
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112969505B (en) 2018-10-31 2023-11-14 吉利德科学公司 Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
HRP20240541T1 (en) 2018-10-31 2024-07-05 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
JP2022513592A (en) 2018-11-02 2022-02-09 シャンハイ マキシノベル ファーマシューティカルズ カンパニー リミテッド Biphenyl compounds, their intermediates, manufacturing methods, pharmaceutical compositions and uses
JP7623279B2 (en) 2018-11-08 2025-01-28 オーリジーン オンコロジー リミテッド Combining small molecule CD47 inhibitors with other anticancer drugs
WO2020109355A1 (en) 2018-11-28 2020-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kit for assaying lytic potential of immune effector cells
US20220018835A1 (en) 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2020127059A1 (en) 2018-12-17 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sulconazole as a furin inhibitor
JP2022518399A (en) 2019-01-14 2022-03-15 ジェネンテック， インコーポレイテッド How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines
JP2022517029A (en) 2019-01-15 2022-03-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Mutant interleukin-34 (IL-34) polypeptide and its use in therapy
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
CN113543851A (en) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2'3' -cyclic dinucleotides and their prodrugs
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN109824621A (en) * 2019-03-28 2019-05-31 中国药科大学 Oxadiazoles and thiadiazoles compounds and preparation method and use thereof
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220160692A1 (en) 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
BR112021020867A2 (en) 2019-04-19 2022-01-04 Genentech Inc Antibodies, nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, uses of the antibody, method of treating an individual with cancer, and method of reducing clearance
WO2020225077A1 (en) 2019-05-03 2020-11-12 Idorsia Pharmaceuticals Ltd Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors
JP2022531970A (en) 2019-05-15 2022-07-12 ケモセントリックス，インコーポレイティド Triaryl compounds for the treatment of PD-L1 disease
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP3976090A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
MX2021015708A (en) 2019-06-20 2022-02-03 Chemocentryx Inc Compounds for treatment of pd-l1 diseases.
HUE066112T2 (en) 2019-07-09 2024-07-28 Idorsia Pharmaceuticals Ltd Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound
KR20220034829A (en) 2019-07-10 2022-03-18 케모센트릭스, 인크. Indan as a PD-L1 inhibitor
EP3997083A1 (en) 2019-07-11 2022-05-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN111718310B (en) * 2019-08-19 2021-06-11 中国药科大学 Phenyl-substituted five-membered heterocyclic compound, and preparation method, application and pharmaceutical composition thereof
CN114286822A (en) 2019-09-30 2022-04-05 南京明德新药研发有限公司 Compounds as small molecule inhibitors of PD-1/PD-L1 and their applications
FI4037708T3 (en) 2019-09-30 2024-10-31 Gilead Sciences Inc HBV VACCINES AND METHODS FOR TREATING HBV
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
JP2022551973A (en) 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Heteroaryl-biphenylamides for the treatment of PD-L1 disease
CN114728905A (en) 2019-11-13 2022-07-08 基因泰克公司 Therapeutic compounds and methods of use
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3163389A1 (en) 2020-01-03 2021-07-08 Mi ZENG Biphenyl derivative inhibitor, preparation method therefor and use thereof
IL294557A (en) 2020-01-07 2022-09-01 Univ Texas Enhanced human methylthioadenosine/adenosine-depleting enzyme variants for cancer therapy
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
TW202421168A (en) 2020-03-20 2024-06-01 美商基利科學股份有限公司 Prodrugs of 4’-c-substituted-2-halo-2’-deoxyadenosine nucleosides and methods of making and using the same
BR112022024063A2 (en) 2020-05-26 2023-01-31 Inst Nat Sante Rech Med CORONAVIRUS 2 POLYPEPTIDES OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS-COV-2) AND USES THEREOF FOR VACCINE PURPOSES
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
TW202214568A (en) 2020-09-09 2022-04-16 大陸商廣州再極醫藥科技有限公司 Aromatic vinyl compound and preparation method, intermediate, pharmaceutical composition thereof and use thereof
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
JP2023551906A (en) 2020-12-02 2023-12-13 ジェネンテック， インコーポレイテッド Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
US20240228659A1 (en) 2021-04-14 2024-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
JP2024516230A (en) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods and compositions for cancer
TW202310852A (en) 2021-05-13 2023-03-16 美商基利科學股份有限公司 Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
JP2024521947A (en) 2021-06-11 2024-06-04 ギリアード サイエンシーズ， インコーポレイテッド Combination of MCL-1 inhibitors with antibody drug conjugates
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CR20230585A (en) 2021-06-23 2024-02-19 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
JP2024524210A (en) 2021-06-23 2024-07-05 ギリアード サイエンシーズ， インコーポレイテッド Diacylglycerol kinase modulating compounds
EP4363449A2 (en) 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
EP4367269A1 (en) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
MX2024001214A (en) 2021-07-28 2024-02-12 Hoffmann La Roche Methods and compositions for treating cancer.
CN118871463A (en) 2021-07-28 2024-10-29 基因泰克公司 Methods and compositions for treating cancer
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325278A (en) 2021-10-26 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6 receptor modulators
WO2023073082A1 (en) 2021-10-28 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
MX2024006003A (en) 2021-11-17 2024-08-06 Inst Nat Sante Rech Med Universal sarbecovirus vaccines.
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
TW202332429A (en) 2021-11-24 2023-08-16 美商建南德克公司 Therapeutic compounds and methods of use
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL316738A (en) 2022-05-11 2024-12-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
TW202417042A (en) 2022-07-13 2024-05-01 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023309556A1 (en) 2022-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
TW202426505A (en) 2022-10-25 2024-07-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2024115549A1 (en) 2022-11-30 2024-06-06 Idorsia Pharmaceuticals Ltd Aryl- and heteroaryl-sulfonamide derivatives as ccr8 modulators
WO2024121138A1 (en) 2022-12-06 2024-06-13 Idorsia Pharmaceuticals Ltd Crystalline adipic acid salt form of a ccr6 antagonist
TW202440154A (en) 2022-12-20 2024-10-16 美商建南德克公司 Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025003193A1 (en) 2023-06-26 2025-01-02 Institut National de la Santé et de la Recherche Médicale Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
TW201311B (en) 1991-06-17 1993-03-01 Hoffmann La Roche
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
WO2001004116A2 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic pyrrolidines and piperidines, and related compositions containing them
ES2539411T3 (en) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receiver for B7-4 and its use
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
AR046787A1 (en) 2003-12-05 2005-12-21 Bristol Myers Squibb Co HETEROCICLIC ANTIMIGRAN AGENTS
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
CN117534755A (en) 2005-05-09 2024-02-09 小野药品工业株式会社 Human monoclonal antibodies to programmed death-1 (PD-1) and methods of treating cancer using anti-PD-1 antibodies
US20090170907A1 (en) 2005-06-06 2009-07-02 Smithkline Beecham Corporation Chemical Compounds
US20090042926A1 (en) 2005-12-20 2009-02-12 Jason Imbriglio Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN101790527A (en) 2006-07-20 2010-07-28 凯利普西斯公司 The kinase whose benzothiophene inhibitors of RHO
US7863456B2 (en) 2006-09-25 2011-01-04 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
CN104945508B (en) 2007-06-18 2019-02-22 默沙东有限责任公司 For the antibody of people's programmed death receptor PD-1
EP2178531A4 (en) 2007-07-02 2012-01-11 Yu Ming Methods, composition, targets for combinational cancer treatments
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CN102083828B (en) 2008-02-22 2013-11-13 Irm责任有限公司 Heterocyclic compounds and compositions as C-KIT and PDGFR kinase inhibitors
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
JP2012507563A (en) 2008-10-30 2012-03-29 エリクシアー ファーマシューティカルズ， インコーポレイテッド Sulfonamide-containing compounds and uses thereof
KR20240093808A (en) 2008-12-09 2024-06-24 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
MX2012005809A (en) 2009-11-24 2012-09-07 Medimmune Ltd Targeted binding agents against b7-h1.
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011137587A1 (en) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012129564A2 (en) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome chymotrypsin-like inhibition using pi-1833 analogs
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
TWI547493B (en) 2011-09-27 2016-09-01 諾華公司 3-pyrimidin-4-yl-oxazolidine-2-one as inhibitor of mutant IDH
CN104159911A (en) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 Peptidomimetic compounds as immunomodulators
JP2015512910A (en) 2012-03-29 2015-04-30 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Immunomodulatory cyclic compounds derived from the BC loop of human PD1
BR112015007672A2 (en) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc human monoclonal anti-pd-l1 antibodies and methods of use
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
EA028033B1 (en) 2013-03-14 2017-09-29 Новартис Аг 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
EP3001615B1 (en) 2013-07-08 2018-09-19 Huawei Technologies Co., Ltd. Bit error rate detecting method and network device
SI3041828T1 (en) 2013-09-06 2018-10-30 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
TR201809838T4 (en) * 2013-09-06 2018-07-23 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators.
EP3702373B9 (en) 2013-09-13 2022-11-23 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2016073470A1 (en) 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
CU20170118A7 (en) 2015-03-10 2018-02-08 Aurigene Discovery Tech Ltd TIADIAZOL AND 1,2,4-OXADIAZOL 3-SUBSTITUTED COMPOUNDS AS IMMUNOMODULATORS
CA2979145A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016142833A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
CN110139856A (en) 2016-10-20 2019-08-16 奥列基因发现技术有限公司 The double inhibitor of VISTA and PD-1 access
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. Crystal forms of immunomodulators
US11136300B2 (en) 2017-10-11 2021-10-05 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
US11497734B2 (en) 2017-11-03 2022-11-15 Aurigene Discovery Technologies Limited Dual inhibitors of TIM-3 and PD-1 pathways
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Graham, B.S., “Clinical trials of HIV vaccines.” HIV Molecular Immunology Database 2000. Edited by: Korber BT, Brander C, Haynes BF, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins D. Published by: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. pp. I-20-38 *
Luo et al. Cell 2009, 136, 823-837 *
Waldmann, T. Annu. Rev. Med. 2006, 57, 65-81 *

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759454B2 (en) 2012-12-07 2023-09-19 Chemocentryx, Inc. Diazole lactams
US10744118B2 (en) 2012-12-07 2020-08-18 Chemocentryx, Inc. Diazole lactams
US9771338B2 (en) * 2013-09-06 2017-09-26 Auirgene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US12037321B2 (en) 2013-09-06 2024-07-16 Aurigene Oncology Limited 1,2,4-oxadiazole derivatives as immunomodulators
US20170101386A1 (en) * 2013-09-06 2017-04-13 Aurigene Discovery Technologies Limited 1,2,4-Oxadiazole Derivatives as Immunomodulators
US10781189B2 (en) * 2015-03-10 2020-09-22 Aurigene Discovery Technologies Limited 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators
EP3747472A1 (en) 2015-09-15 2020-12-09 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
US11744822B2 (en) 2016-04-07 2023-09-05 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
US10568870B2 (en) 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) * 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) * 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
US10415015B2 (en) 2016-10-31 2019-09-17 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
US11667890B2 (en) 2016-10-31 2023-06-06 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
EP4302833A3 (en) * 2016-12-02 2024-03-13 Augusta University Research Institute, Inc. Compositions for modulating pd-1 signal transduction
WO2018100556A1 (en) 2016-12-02 2018-06-07 Augusta University Research Institute, Inc. Compositions for modulating pd-1 signal transduction
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
TWI808955B (en) * 2016-12-22 2023-07-21 美商英塞特公司 Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017382258B2 (en) * 2016-12-22 2022-07-28 Incyte Corporation Tetrahydro imidazo(4,5-c)pyridine derivatives as PD-L1 internalization inducers
CN110267953A (en) * 2016-12-22 2019-09-20 因赛特公司 Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 internalization inducers
TWI798192B (en) * 2016-12-22 2023-04-11 美商英塞特公司 Immunomodulator compounds and methods of use
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
US11643401B2 (en) 2017-09-29 2023-05-09 Curis, Inc. Crystal forms of immunomodulators
US11939306B2 (en) 2017-09-29 2024-03-26 Curis, Inc. Crystal forms of immunomodulators
US11040948B2 (en) * 2017-09-29 2021-06-22 Curis, Inc. Crystal forms of immunomodulators
US11680051B2 (en) 2017-10-11 2023-06-20 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
US12187689B2 (en) 2017-10-11 2025-01-07 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
AU2018360386B2 (en) * 2017-11-03 2023-11-09 Aurigene Oncology Limited Dual inhibitors of TIM-3 and PD-1 pathways
WO2019087087A1 (en) * 2017-11-03 2019-05-09 Aurigene Discovery Technologies Limited Dual inhibitors of tim-3 and pd-1 pathways
CN111372584A (en) * 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Dual inhibitors of the TIM-3 and PD-1 pathways
US12064418B2 (en) 2017-11-06 2024-08-20 Curis, Inc. Conjoint therapies for immunomodulation
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US12187743B2 (en) 2018-05-11 2025-01-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4378530A2 (en) 2018-08-31 2024-06-05 Iovance Biotherapeutics, Inc. Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
WO2020096682A2 (en) 2018-08-31 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
EP4059569A1 (en) 2019-01-03 2022-09-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2022094567A1 (en) 2020-10-28 2022-05-05 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US12084443B2 (en) 2020-11-06 2024-09-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11981921B2 (en) 2022-04-15 2024-05-14 Iovance Biotherapeutics, Inc. TIL expansion processes using specific cytokine combinations and/or AKTi treatment
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy

Also Published As

Publication number Publication date
AU2018271231B2 (en) 2020-06-25
IL268035A (en) 2019-09-26
PT3363790T (en) 2020-05-06
BR112016004889B1 (en) 2023-10-03
CN108164474B (en) 2022-05-17
HRP20200703T1 (en) 2020-09-04
CA2922607A1 (en) 2015-03-12
US11512060B2 (en) 2022-11-29
PL3363790T3 (en) 2020-07-27
JP2016532710A (en) 2016-10-20
US9233940B2 (en) 2016-01-12
IL244314A (en) 2017-09-28
ES2788848T3 (en) 2020-10-23
HRP20181052T1 (en) 2018-09-07
JP6521977B2 (en) 2019-05-29
MX365218B (en) 2019-05-27
DK3363790T3 (en) 2020-04-27
MX2016002969A (en) 2016-10-07
EP3363790A1 (en) 2018-08-22
US9771338B2 (en) 2017-09-26
CN108164474A (en) 2018-06-15
US20150073042A1 (en) 2015-03-12
AU2020239615A1 (en) 2020-10-15
EP3041827A1 (en) 2016-07-13
BR112016004889A2 (en) 2017-08-01
CN105814028B (en) 2018-02-16
NZ718711A (en) 2021-10-29
EP3041827B1 (en) 2018-04-18
US20190144402A1 (en) 2019-05-16
SMT202000283T1 (en) 2020-07-08
AU2022241543A1 (en) 2022-10-27
IL244314A0 (en) 2016-04-21
US10173989B2 (en) 2019-01-08
US20170101386A1 (en) 2017-04-13
LT3041827T (en) 2018-07-25
HUE038169T2 (en) 2018-09-28
PL3041827T3 (en) 2018-09-28
HUE048874T2 (en) 2020-08-28
EA030155B1 (en) 2018-06-29
RS57508B1 (en) 2018-10-31
PT3041827T (en) 2018-07-09
SG11201601682RA (en) 2016-04-28
AU2022241543B2 (en) 2024-05-23
US20210198219A1 (en) 2021-07-01
CY1122986T1 (en) 2021-10-29
US10961205B2 (en) 2021-03-30
WO2015033299A1 (en) 2015-03-12
CA2922607C (en) 2022-08-30
IL253651B (en) 2019-07-31
AU2014316682B2 (en) 2018-11-22
AU2020239615B2 (en) 2022-07-07
DK3041827T3 (en) 2018-07-16
CN105814028A (en) 2016-07-27
US20180072689A1 (en) 2018-03-15
US20200199086A1 (en) 2020-06-25
SMT201800376T1 (en) 2018-09-13
ES2675027T3 (en) 2018-07-05
US12037321B2 (en) 2024-07-16
AU2024213135A1 (en) 2024-09-12
SI3041827T1 (en) 2018-09-28
TR201809838T4 (en) 2018-07-23
MY186438A (en) 2021-07-22
AU2014316682A1 (en) 2016-04-28
CY1120899T1 (en) 2019-12-11
IL268035B (en) 2020-04-30
US10590093B2 (en) 2020-03-17
EA201600236A1 (en) 2016-08-31
KR20160081897A (en) 2016-07-08
SI3363790T1 (en) 2020-08-31
AU2018271231A1 (en) 2018-12-13
PH12016500406B1 (en) 2016-05-16
EP3363790B1 (en) 2020-02-19
KR102362277B1 (en) 2022-02-11
US20240400525A1 (en) 2024-12-05
ZA201602193B (en) 2022-11-30
US20230167076A1 (en) 2023-06-01
IL253651A0 (en) 2017-09-28
CU24362B1 (en) 2018-10-04
PH12016500406A1 (en) 2016-05-16
LT3363790T (en) 2020-05-11
RS60317B1 (en) 2020-07-31
CU20160029A7 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
US12037321B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
US10160736B2 (en) 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
US10106581B2 (en) Cyclic peptidomimetic compounds as immunomodulators
NZ718711B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators

Legal Events

Date Code Title Description
AS Assignment

Owner name: AURIGENE DISCOVERY TECHNOLOGIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SASIKUMAR, POTTAYIL GOVINDAN NAIR;RAMACHANDRA, MURALIDHARA;NAREMADDEPALLI, SEETHARAMAIAH SETTY SUDARSHAN;SIGNING DATES FROM 20160404 TO 20160405;REEL/FRAME:038188/0666

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: AURIGENE ONCOLOGY LIMITED, INDIA

Free format text: CHANGE OF NAME;ASSIGNOR:AURIGENE DISCOVERY TECHNOLOGIES LIMITED;REEL/FRAME:063654/0411

Effective date: 20221207